Table 1a. Clinical characteristics of colorectal cancer cases in the NSHDS cohort.
| |
Quadruple Index |
KRAS |
BRAF |
PIK3CA Exon20 |
PTEN |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Negative | Positive | P-value | Wt | Mutant | P-value | Wt | Mutant | P-value | Wt | Mutant | P-value | Normal | Loss | P-value | |
| Frequency (%) |
197 |
89 (51.7) |
83 (48.3) |
|
147 (82.1) |
32 (17.9) |
|
161 (82.1) |
35 (17.9) |
|
182 (97.8) |
4 (2.2) |
|
161 (87.5) |
23 (12.5) |
|
| Age, n (%) |
|
|
|
0.524 |
|
|
0.141 |
|
|
0.451 |
|
|
0.853 |
|
|
0.072 |
| <59 |
57 (28.9) |
24 (27.0) |
24 (28.9) |
|
36 (24.5) |
13 (40.6) |
|
49 (30.4) |
8 (22.9) |
|
53 (29.1) |
1 (25.0) |
|
50 (31.1) |
4 (17.4) |
|
| 60–69 |
111 (56.3) |
50 (56.2) |
50 (60.2) |
|
90 (61.2) |
14 (43.8) |
|
87 (54.0) |
23 (65.7) |
|
102 (56.0) |
2 (50.0) |
|
86 (53.4) |
18 (78.3) |
|
| 70–79 |
29 (14.7) |
15 (16.9) |
9 (10.8) |
|
21 (14.3) |
5 (15.6) |
|
25 (15.5) |
4 (11.4) |
|
27 (14.8) |
1 (25.0) |
|
25 (15.5) |
1 (4.3) |
|
| >80 |
— |
— |
— |
|
— |
— |
|
— |
— |
|
— |
— |
|
— |
— |
|
| Sex, n (%) |
|
|
|
0.319 |
|
|
0.276 |
|
|
0.258 |
|
|
0.191 |
|
|
0.339 |
| Men |
85 (43.1) |
41 (46.1) |
32 (38.6) |
|
66 (44.9) |
11 (34.4) |
|
72 (44.7) |
12 (34.3) |
|
77 (42.3) |
3 (75.0) |
|
67 (41.6) |
12 (52.2) |
|
| Women |
112 (56.9) |
48 (53.9) |
51 (61.4) |
|
81 (55.1) |
21 (65.6) |
|
89 (55.3) |
23 (65.7) |
|
105 (57.7) |
1 (25.0) |
|
94 (58.4) |
11 (47.8) |
|
| Tumour site, n (%) |
|
|
|
<0.001 |
|
|
0.033 |
|
|
<0.001 |
|
|
0.894 |
|
|
0.726 |
| Right-sided colon |
62 (31.5) |
16 (18.0) |
41 (49.4) |
|
43 (29.3) |
14 (43.8) |
|
37 (23.0) |
25 (71.4) |
|
59 (32.4) |
1 (25.0) |
|
50 (31.1) |
8 (34.8) |
|
| Left-sided colon |
57 (28.9) |
25 (28.1) |
24 (28.9) |
|
40 (27.2) |
12 (37.5) |
|
49 (30.4) |
8 (22.9) |
|
53 (29.1) |
1 (25.0) |
|
48 (29.8) |
5 (21.7) |
|
| Rectum |
78 (39.6) |
48 (53.9) |
18 (21.7) |
|
64 (43.5) |
6 (18.8) |
|
75 (46.6) |
2 (5.7) |
|
70 (38.5) |
2 (50.0) |
|
63 (39.1) |
10 (43.5) |
|
| Stage, n (%) |
|
|
|
0.004 |
|
|
0.799 |
|
|
0.001 |
|
|
0.965 |
|
|
0.047 |
| I |
36 (18.4) |
19 (21.3) |
10 (12.0) |
|
28 (19.0) |
5 (15.6) |
|
34 (21.3) |
2 (5.7) |
|
33 (18.1) |
1 (25.0) |
|
29 (18.1) |
2 (8.7) |
|
| II |
69 (35.2) |
36 (40.4) |
23 (27.7) |
|
54 (36.7) |
10 (31.3) |
|
57 (35.6) |
12 (34.3) |
|
67 (36.8) |
1 (25.0) |
|
60 (37.5) |
4 (17.4) |
|
| III |
46 (23.5) |
22 (24.7) |
20 (24.1) |
|
34 (23.1) |
8 (25.0) |
|
41 (25.6) |
5 (14.3) |
|
42 (23.1) |
1 (25.0) |
|
34 (21.3) |
10 (43.5) |
|
| IV |
45 (23.0) |
12 (13.5) |
30 (36.1) |
|
31 (21.1) |
9 (28.1) |
|
28 (17.5) |
16 (45.7) |
|
40 (22.0) |
1 (25.0) |
|
37 (23.1) |
7 (30.4) |
|
| Histology type, n (%) |
|
|
|
0.567 |
|
|
0.526 |
|
|
0.134 |
|
|
0.329 |
|
|
0.846 |
| Non-mucinous |
158 (80.6) |
71 (80.7) |
64 (77.1) |
|
116 (79.5) |
27 (84.4) |
|
132 (82.5) |
25 (71.4) |
|
146 (80.7) |
4 (100.0) |
|
128 (80.0) |
18 (78.3) |
|
| Mucinous | 38 (19.4) | 17 (19.3) | 19 (22.9) | 30 (20.5) | 5 (15.6) | 28 (17.5) | 10 (28.6) | 35 (19.3) | 0 (0.0) | 32 (20.0) | 5 (21.7) | |||||
Abbreviations: NSHDS=Northern Sweden Health Disease Study; Wt=wild-type.
Following numbers of missing cases were present in NSHDS: Quadruple Index, 25; KRAS mutation status, 18; BRAF mutation status, 1; PIK3CA mutation status, 11; PTEN mutation status, 13; Stage, 1; Histology type, 1; Adjuvant chemotherapy, 11; Preoperative, 2. Kruskal–Wallis test was used for continuous variables, χ2-test or Fisher's exact test used for categorical variables.